This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matzku, S. Articles by Tilgen, W. Search for Related Content PubMed PubMed Citation Articles by Matzku, S. Articles by Tilgen, W.

Modes of Binding and Internalization of Monoclonal Antibodies to Human Melanoma Cell Lines¹

German Cancer Research Center, Institute of Nuclear Medicine, D-6900 Heidelberg [S. M.]; Department of Experimental Dermatology, Westfälische Wilhelms-Universität, D-4400 Münster, [E-B. B., J. B.]; I. Med. Klinik und Poliklinik, Johannes Gutenberg-Universität, D-6500 Mainz [W. G. D.]; and Universitäts-Hautklinik, D-6900 Heidelberg [W. T.], Germany

The process of monoclonal antibody (MAb) binding to tumor cells is greatly influenced by the biology of the respective antigen. This was concluded from an analysis of binding and release of MAbs and MAb fragments to melanoma cells at different concentration levels and different temperatures. With an antigen known to be stably expressed at the cell surface (i.e., M_r 97,000 protein) rapid binding of MAbs was observed at both 0°C and 37°C, and this was reversed by treatment with isoosmolar acid buffer. With another group of antigens, MAb binding increased continuously up to considerable levels at 37°C, but not at 0°C. Concomitantly, the portion of radioactive MAb not desorbable by acid buffer treatment increased, pointing to temperature-dependent internalization. With still another group of (glycolipid) antigens, the highest MAb binding was obtained with fixed cells at 0°C. In this situation MAb release was particularly rapid, thus pointing to a shedding process.

¹ This work was supported by the Sonderforschungsbereich 136 "Krebsforschung," Deutsche Forschungsgemeinschaft.

² To whom requests for reprints should be addressed, at Pf. 101949, D-6900 Heidelberg, Germany.

Received 7/ 2/85. Revised 2/12/86. Accepted 4/30/86.

This article has been cited by other articles:

				I. Burvenich, S. Schoonooghe, B. Cornelissen, P. Blanckaert, E. Coene, C. Cuvelier, N. Mertens, and G. Slegers In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131-Labeled Monoclonal Antibody 14C5 in a Non-Small Cell Lung Cancer and Colon Carcinoma Model Clin. Cancer Res., October 15, 2005; 11(20): 7288 - 7296. [Abstract] [Full Text] [PDF]